参考文献[2]
ZhouF, YuT, DuRH, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study[J]. Lancet, 2020, 395(10229): 1054-1062. .
[3]
CummingsMJ, BaldwinMR, AbramsD, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study[J]. Lancet, 2020, 395(10239): 1763-1770. .
[4]
HuangCL, WangYM, LiXW, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506..
[5]
GrasselliG, ZangrilloA, ZanellaA, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy[J]. JAMA, 2020, 323(16): 1574-1581. .
[6]
WuZY, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention[J]. JAMA, 2020, 323(13): 1239-1242.
[7]
VerityR, Okell LC, DorigattiI, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis[J]. Lancet Infect Dis, 2020, 20(6): 669-677. .
[8]
CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19)-United States, February 12-March 16, 2020[J]. MMWR Morb Mortal Wkly Rep, 2020, 69(12): 343-346. .
[9]
Choi KW, Chau TN, TsangO, et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong[J]. Ann Intern Med, 2003,139(9):715-723..
[10]
Hong KH, Choi JP, Hong SH, et al. Predictors of mortality in Middle East respiratory syndrome (MERS)[J]. Thorax, 2018, 73(3): 286-289. .
[11]
KimballA, Hatfield KM, AronsM, et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020[J]. MMWR Morb Mortal Wkly Rep, 2020, 69(13): 377-381. .
[12]
Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility[J]. N Engl J Med, 2020, 382(22): 2081-2090. .
[13]
Patel MC, Chaisson LH, BorgettiS, et al. Asymptomatic SARS-CoV-2 infection and COVID-19 mortality during an outbreak investigation in a skilled nursing facility[J]. Clin Infect Dis, 2020. .
[14]
SaljeH, TranKC, LefrancqN, et al. Estimating the burden of SARS-CoV-2 in France[J]. Science, 2020, 369(6500): 208-211..
[15]
ChenNS, ZhouM, DongX, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223): 507-513. .
[16]
中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组. 新型冠状病毒肺炎流行病学特征分析[J]. 中华流行病学杂志, 2020, 41(2): 145-151. .
[18]
Leung GM, Hedley AJ, Ho LM, et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients[J]. Ann Intern Med, 2004, 141(9): 662-673. .
[19]
MatsuyamaR, NishiuraH, KutsunaS, et al. Clinical determinants of the severity of Middle East respiratory syndrome (MERS): a systematic review and meta-analysis[J]. BMC Public Health, 2016, 16(1): 1203. .
[20]
Klein SL, Flanagan KL. Sex differences in immune responses[J]. Nat Rev Immunol, 2016, 16(10): 626-638. .
[21]
Giefing-KrollC, BergerP, LepperdingerG, et al. How sex and age affect immune responses, susceptibility to infections, and response to vaccination[J]. Aging Cell, 2015, 14(3): 309-321. .
[22]
ChenZM, PetoR, ZhouMG, et al. Contrasting male and female trends in tobacco-attributed mortality in China: evidence from successive nationwide prospective cohort studies[J]. Lancet, 2015, 386(10002): 1447-1456. .
[23]
Sama IE, RaveraA, Santema BT, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors[J]. Eur Heart J, 2020, 41(19): 1810-1817. .
[24]
StrzelakA, RatajczakA, AdamiecA, et al. Tobacco Smoke Induces and Alters Immune Responses in the Lung Triggering Inflammation, Allergy, Asthma and Other Lung Diseases: A Mechanistic Review[J]. Int J Environ Res Public Health, 2018, 15(5): 1033. .
[25]
HoffmannM, Kleine-WeberH, SchroederS, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor[J]. Cell, 2020, 181(2): 271-280. .
[26]
YangJ, ZhengY, GouX, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis[J]. Int J Infect Dis, 2020, 94: 91-95. .
[27]
StefanN, Birkenfeld AL, Schulze MB, et al. Obesity and impaired metabolic health in patients with COVID-19[J]. Nat Rev Endocrinol, 2020, 16(7): 341-342. .
[28]
Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area[J]. JAMA, 2003, 289(21): 2801-2809. .
[29]
AllardR, LeclercP, TremblayC, et al. Diabetes and the severity of pandemic influenza A (H1N1) infection[J]. Diabetes Care, 2010, 33(7): 1491-1493. .
[30]
Memish ZA, PerlmanS, Van Kerkhove MD, et al. Middle East respiratory syndrome[J]. Lancet, 2020, 395(10229): 1063-1077. .
[31]
BodeB, GarrettV, MesslerJ, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States[J]. J Diabetes Sci Technol, 2020, 14(4): 813-821. .
[32]
SarduC, D'OnofrioN, Balestrieri ML, et al. Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?[J]. Diabetes Care, 2020, 43(7): 1408-1415. .
[33]
ZhuLH, She ZG, ChengX, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes[J]. Cell Metab, 2020, 31(6): 1068-1077. .
[34]
LiJY, WangXF, ChenJ, et al. COVID-19 infection may cause ketosis and ketoacidosis[J]. Diabetes Obes Metab, 2020. .
[35]
RenHH, YangY, WangF, et al. Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19[J]. Cardiovasc Diabetol, 2020, 19(1): 58. .
[36]
Hotamisligil GS. Inflammation and metabolic disorders[J]. Nature, 2006, 444(7121): 860-867. .
[37]
XuZ, ShiL, WangYJ, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4): 420-422. .
[38]
SimonnetA, ChetbounM, PoissyJ, et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation[J]. Obesity (Silver Spring), 2020, 28(7): 1195-1199. .
[39]
CaiQX, ChenFJ, WangT, et al. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China[J]. Diabetes Care, 2020, 43(7): 1392-1398. .
[40]
WangJF, XuXT, ZhouXB, et al. Molecular simulation of SARS-CoV-2 spike protein binding to pangolin ACE2 or human ACE2 natural variants reveals altered susceptibility to infection[J]. J Gen Virol, 2020, 101(9): 921-924. .
[41]
CaoYN, LiL, FengZM, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations[J]. Cell Discov, 2020, 6: 11. .
[42]
EllinghausD, DegenhardtF, BujandaL, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure[J]. New England Journal of Medicine, 2020, 383: 1522-1534. .
[43]
ZietzM, Tatonetti NP. Testing the association between blood type and COVID-19 infection, intubation, and death[J]. medRxiv, 2020: 2020-2024. .
[44]
PouraliF, AfshariM, Alizadeh-NavaeiR, et al. Relationship Between Blood Group and Risk of Infection and Death in COVID-19: a live Meta-Analysis[J]. medRxiv, 2020: 2020-2026. .
[45]
LeungK, Wu JT, LiuD, et al. First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment[J]. Lancet, 2020, 395(10233): 1382-1393. .
[46]
Khalatbari-SoltaniS, Cumming RC, DelpierreC, et al. Importance of collecting data on socioeconomic determinants from the early stage of the COVID-19 outbreak onwards[J]. J Epidemiol Community Health, 2020, 74(8): 620-623. .
[47]
Williamson EJ, Walker AJ, BhaskaranK, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients[J]. Nature, 2020,584:430-436. .
[48]
Scarpino SV, Scott JG, Eggo RM, et al. Socioeconomic bias in influenza surveillance[J]. PLoS Comput Biol, 2020, 16(7): e1007941. .
[49]
ShiY, YuX, ZhaoH, et al. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan[J]. Crit Care, 2020, 24(1): 108. .
[50]
AssiriA, Abedi GR, Al MM, et al. Middle East Respiratory Syndrome Coronavirus Infection During Pregnancy: A Report of 5 Cases From Saudi Arabia[J]. Clin Infect Dis, 2016, 63(7): 951-953. .
[51]
SistonAM, RasmussenSA, HoneinMA, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States[J]. JAMA, 2010, 303(15): 1517-1525. .
[52]
WongSF, ChowKM, LeungTN, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome[J]. Am J Obstet Gynecol, 2004,191(1): 292-297. .
[53]
ZhuHP, WangL, FangCZ, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia[J]. Transl Pediatr, 2020, 9(1): 51-60. .
[54]
Di MascioD, KhalilA, SacconeG, et al. Outcome of Coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis[J]. Am J Obstet Gynecol MFM, 2020, 2(2): 100-107. .
[55]
VivantiAJ, Vauloup-FellousC, PrevotS, et al. Transplacental transmission of SARS-CoV-2 infection[J]. Nat Commun, 2020,11(1): 3572. .
[56]
ChenHJ, GuoJJ, WangC, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records[J]. Lancet, 2020, 395(10226): 809-815. .
[57]
WangXT, ZhouZQ, ZhangJP, et al. A Case of 2019 Novel Coronavirus in a Pregnant Woman With Preterm Delivery[J]. Clin Infect Dis, 2020, 71(15): 844-846. .
[58]
LiY, ZhaoRH, ZhengSF, et al. Lack of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, China[J]. Emerg Infect Dis, 2020, 26(6): 1335-1336. .
[59]
WuXJ, CaiY, HuangX, et al. Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China[J]. Emerg Infect Dis, 2020, 26(6): 1324-1326. .
[60]
ZhaoJJ, LiaoXJ, WangHY, et al. Early virus clearance and delayed antibody response in a case of COVID-19 with a history of co-infection with HIV-1 and HCV[J]. Clin Infect Dis, 2020, 71(16): 2233-2235. .
[61]
KimD, QuinnJ, PinskyB, et al. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens[J]. JAMA, 2020, 323(20): 2085-2086. .
[62]
BraunJ, LoyalL, FrentschM, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19[J]. Nature, 2020, 587: 270-274. .
[63]
MateusJ, GrifoniA, TarkeA, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans[J]. Science, 2020, 370(6512): 89-94. .
[64]
GrifoniA, WeiskopfD, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals[J]. Cell, 2020, 181(7): 1489-1501. .
[65]
YoungBE, FongS, ChanY, et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study[J]. The Lancet, 2020, 396(10251): 603-611. .
[66]
HuJ, HeCL, GaoQZ, et al. The D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity and decreases neutralization sensitivity to individual convalescent sera[J]. bioRxiv, 2020:2020-2026. .
[67]
ZhangLZ, JacksonCB, MouHH, et al. ZhangLZ, JacksonCB, MouHH, et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun, 2020, 11(1): 6013. .
[68]
DaniloskiZ, GuoX, Sanjana NE. The D614G mutation in SARS-CoV-2 Spike increases transduction of multiple human cell types[J]. bioRxiv, 2020: 2020-2026. .
[69]
IliePC, StefanescuS, SmithL. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality[J]. Aging Clin Exp Res, 2020, 32(7): 1195-1198. .
[70]
ExtermannM. Measuring comorbidity in older cancer patients[J]. Eur J Cancer, 2000, 36(4): 453-471. .
[71]
LiangWH, GuanWJ, ChenRC, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China[J]. Lancet Oncol, 2020, 21(3): 335-337. .
[72]
ZhangL, ZhuF, XieL, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China[J]. Ann Oncol, 2020, 31(7): 894-901. .